LYFAX Mutual Fund

NAV$18.22

Fund Essentials - as of Mar 31, 2026

Net Assets
$5M
Expense Ratio
1.71%
Dividend Yield (Current)
1.21%
Holdings
63
Inception Date
Nov 29, 2019
Fund Family
Alpha Centric Fund
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+17.96%
1 Year+54.34%
3 Year+13.10%
5 Year+8.48%

Asset Allocation

Stocks: 92.29%
Cash: 7.71%

Top Holdings

View All →
TickerNameWeight
FXFXXFirst Am Treas Obli-X7.72%
GILDGilead Sciences Inc7.18%
AZN:LNAstrazeneca Plc5.63%
VRTXNvaesrtex Pharmaceuticals Inc5.60%
IONSIonis Pharmaceuticals Inc3.74%
Top 10 Concentration: 46.76%Report Date: Mar 31, 2026
Download all 63 holdings for LYFAX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
1.21%
Frequency
Annually
Latest Distribution
$1.65
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

LYFAX Mutual Fund Overview

LYFAX Mutual Fund (AlphaCentric Life Sciences and Healthcare Fund Class A) is managed by Alpha Centric Fund with $5.0M in net assets. LYFAX expense ratio is 1.71%, holding 63 positions across sectors including Health Care, Unknown, Financials. Inception date: 2019-11-29.

LYFAX performance shows a YTD return of 17.96%. The 1-year return is 54.34% and the 5-year return is 8.48%. LYFAX dividend yield stands at 1.21%, paid annually.

LYFAX top holdings include First Am Treas Obli-X (7.7%), Gilead Sciences Inc (7.2%), Astrazeneca Plc (5.6%), Nvaesrtex Pharmaceuticals Inc (5.6%), Ionis Pharmaceuticals Inc (3.7%). View all LYFAX holdings, sector breakdown, or dividend history.

LYFAX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LYFAX alternatives are available via the screener, along with tax-loss harvesting opportunities.